Published in Infect Immun on May 01, 1993
Macrophages in resistance to candidiasis. Microbiol Mol Biol Rev (1997) 1.74
Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev (1995) 1.32
Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans. Infect Immun (1997) 0.91
Polymyxin B stimulates production of complement components and cytokines in human monocytes. Antimicrob Agents Chemother (1995) 0.79
Hematopoietic growth factors in cancer patients with invasive fungal infections. Eur J Clin Microbiol Infect Dis (1997) 0.78
Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med (1980) 3.50
Macrophage microbicidal activity. Correlation between phagocytosis-associated oxidative metabolism and the killing of Candida by macrophages. J Exp Med (1980) 2.96
Complement ligand-receptor interactions that mediate biological responses. Annu Rev Immunol (1983) 2.78
Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan. J Exp Med (1984) 2.53
An iC3b receptor on Candida albicans: structure, function, and correlates for pathogenicity. J Infect Dis (1988) 2.07
In vitro differentiation of human monocytes. Differences in monocyte phenotypes induced by cultivation on glass or on collagen. J Exp Med (1982) 2.02
Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J Immunol (1988) 1.70
Pretranslational regulation of the synthesis of the third component of complement in human mononuclear phagocytes by the lipid A portion of lipopolysaccharide. J Clin Invest (1985) 1.45
Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes. Biochem J (1983) 1.40
Stimulation of phagocytosis in bone marrow-derived mouse macrophages by bacterial lipopolysaccharide: correlation with biochemical and functional parameters. J Immunol (1984) 1.36
Hemopoietic growth factors: a review. Cancer Res (1988) 1.31
Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF): IL-3, granulocyte-macrophage-CSF, and macrophage-CSF. J Immunol (1989) 1.30
Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis (1990) 1.18
Complement biosynthesis in human breast-milk macrophages and blood monocytes. Immunology (1982) 1.17
Activation and binding of C3 by Candida albicans. Infect Immun (1987) 1.17
Synthesis of complement by macrophages and modulation of their functions through complement activation. Springer Semin Immunopathol (1983) 1.10
C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J Immunol (1987) 1.10
Modulation of monocyte complement synthesis by interferons. Biochem J (1987) 1.08
Production of granulocyte-macrophage colony-stimulating factor (GM-CSF) by monocytes and large granular lymphocytes stimulated with Mycobacterium avium-M. intracellulare: activation of bactericidal activity by GM-CSF. Infect Immun (1991) 1.07
Phagocytosis of Leishmania enhances macrophage activation by IFN-gamma and lipopolysaccharide. J Immunol (1991) 1.07
Regulation of human polymorphonuclear neutrophil (PMN) activity against Candida albicans by large granular lymphocytes via release of a PMN-activating factor. J Immunol (1987) 1.07
The role of complement and antibody in opsonization and intracellular killing of Candida albicans. Clin Exp Immunol (1984) 1.03
The colony stimulating factors. Discovery, development, and clinical applications. Cancer (1990) 1.02
Mononuclear phagocytes have the potential to synthesize the complete functional complement system. Scand J Immunol (1988) 1.00
Granulocyte-macrophage colony-stimulating factor increases the infectivity of Leishmania amazonensis by protecting promastigotes from heat-induced death. Infect Immun (1992) 0.99
Synthesis of complement components (C3, C2, B and C1-inhibitor) and lysozyme by human monocytes and macrophages. J Clin Lab Immunol (1986) 0.97
Long term cultures of human monocytes in vitro. Impact of GM-CSF on survival and differentiation. J Immunol Methods (1991) 0.96
Enhancement of monocyte complement component synthesis by antigen--antibody complexes. Immunology (1981) 0.93
Differential expression of M-CSF, G-CSF, and GM-CSF by human monocytes. J Leukoc Biol (1990) 0.93
Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures. Lymphokine Cytokine Res (1991) 0.91
Synthesis of complement components C5, C6, C7, C8 and C9 in vitro by human monocytes and assembly of the terminal complement complex. Scand J Immunol (1986) 0.90
Stimulation of complement component C3 synthesis in macrophagelike cell lines by group B streptococci. Infect Immun (1987) 0.90
Regulation of the synthesis of the third component of complement and factor B in cord blood monocytes by lipopolysaccharide. J Immunol (1986) 0.85
Modulation of phagocytosis induced prostaglandin release from macrophages. Adv Exp Med Biol (1979) 0.81
Phagocytosis inhibits the production of C2 by human monocytes. Int Arch Allergy Appl Immunol (1983) 0.80
Complement proteins and macrophages. III. The production of factor B by particle-ingesting macrophages. Microbiol Immunol (1981) 0.76
Biological properties in vitro of a combination of recombinant murine interleukin-3 and granulocyte-macrophage colony-stimulating factor. Eur J Haematol (1989) 0.76
V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood (2001) 2.50
Elution and characterization of lymphocytes from rheumatoid inflammatory tissue. Scand J Immunol (1975) 1.60
Primary immunodeficiency diseases in Norway. J Clin Immunol (2000) 1.48
Persistent strains of coagulase-negative staphylococci in a neonatal intensive care unit: virulence factors and invasiveness. Clin Microbiol Infect (2007) 1.43
[Diagnosis and treatment of infections in a neonatal unit--viral infections, spirochete infections and toxoplasma infections]. Tidsskr Nor Laegeforen (1993) 1.39
Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. J Hosp Infect (2001) 1.09
Rheumatoid factor plaque-forming cells in rheumatoid synovial tissue. Clin Exp Immunol (1977) 1.05
CD40lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome. Immunol Today (1996) 1.00
Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation. J Immunol (1995) 1.00
Membrane characteristics of adherent cells dissociated from rheumatoid synovial tissue. Clin Exp Immunol (1977) 0.97
In vitro mitogen stimulation of synovial fluid lymphocytes from rheumatoid arthritis and juvenile rheumatoid arthritis patients: dissociation between the response to antigens and polyclonal mitogens. Scand J Immunol (1978) 0.96
Granulocyte-macrophage colony-stimulating factor, but not macrophage colony-stimulating factor, suppresses basal and lipopolysaccharide-stimulated complement factor production in human monocytes. J Immunol (1993) 0.95
Psychological outcome in children treated for brain tumor. Pediatr Hematol Oncol (1999) 0.93
Oral administration of a new soluble branched beta-1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers. Clin Exp Immunol (2006) 0.91
Antigen and unspecific mitogen stimulation of lymphocytes eluted from rheumatoid inflammatory tissue. Scand J Immunol (1976) 0.89
Low thymic output in the 22q11.2 deletion syndrome measured by CCR9+CD45RA+ T cell counts and T cell receptor rearrangement excision circles. Clin Exp Immunol (2010) 0.88
Blood culture isolates during 6 years in a tertiary neonatal intensive care unit. Scand J Infect Dis (1998) 0.88
Familial disseminated infection due to atypical mycobacteria with childhood onset. Clin Infect Dis (1998) 0.86
Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia. Clin Exp Immunol (2005) 0.85
Discrepancy between results of a commercial enzyme immunoassay kit and immunofluorescence staining for detection of respiratory syncytial virus antigen. Eur J Clin Microbiol Infect Dis (1998) 0.82
Alpha fetoprotein is increasing with age in ataxia-telangiectasia. Eur J Paediatr Neurol (2007) 0.82
The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents. Clin Exp Immunol (2004) 0.81
Granulocyte colony-stimulating factor receptor mutations in a patient with acute lymphoblastic leukemia secondary to severe congenital neutropenia. Blood (2001) 0.80
Absence of modulation of monokine production via endogenous cyclooxygenase or 5-lipoxygenase metabolites: MK-886 (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2- dimethylpropanoic acid), indomethacin, or arachidonate fail to alter immunoreactive interleukin-1 beta, or TNF-alpha production by human monocytes in vitro. Clin Immunol Immunopathol (1991) 0.80
Acremonium strictum fungaemia in a paediatric patient with acute leukaemia. Scand J Infect Dis (2000) 0.80
Modulation of C3 gene expression in HepG2 human hepatoma cells. Immunol Lett (2001) 0.79
The analysis of the complement activation product SC5 b-9 is applicable in neonates in spite of their profound C9 deficiency. J Perinat Med (2000) 0.79
Polymyxin B stimulates production of complement components and cytokines in human monocytes. Antimicrob Agents Chemother (1995) 0.79
Calcium-dependent eicosanoid metabolism by concanavalin A-stimulated human monocytes in vitro. Synergism with phorbol ester indicates separate regulation of leukotriene B4 synthesis and release. J Immunol (1991) 0.79
C-reactive protein (CRP) response patterns in neonatal septicaemia. APMIS (1999) 0.78
Transforming growth factor beta modulates C3 and factor B biosynthesis and complement receptor 3 expression in cultured human monocytes. J Leukoc Biol (1995) 0.78
Point-of-use filtration method for the prevention of fungal contamination of hospital water. J Hosp Infect (2010) 0.78
Direct growth suppression of myeloid bone marrow progenitor cells but not cord blood progenitors by human cytomegalovirus in vitro. Blood (1996) 0.78
Lymphocytes eluted from synovial tissue of juvenile rheumatoid arthritis patients. Arthritis Rheum (1977) 0.78
Various Candida and Torulopsis species differ in their ability to induce the production of C3, factor B and granulocyte-macrophage colony-stimulating factor (GM-CSF) in human monocyte cultures. J Med Microbiol (1995) 0.78
Heparin suppresses lipopolysaccharide-induced monocyte production of several cytokines, but simultaneously stimulates C3 production. Thromb Res (1995) 0.77
Alterations in the terminal complement pathway in leukopenic children with malignant diseases during episodes with evidence of infection. Complement Inflamm (1989) 0.77
X-linked thrombocytopenia and thrombocytopathia: attenuated Wiskott-Aldrich syndrome. Functional and morphological studies of platelets and lymphocytes. Thromb Haemost (1991) 0.77
[Salmonella infection from turtles]. Tidsskr Nor Laegeforen (2000) 0.76
[Cytomegalovirus infection in neonates. Diagnosis and therapeutic experiences]. Tidsskr Nor Laegeforen (1997) 0.75
Plaque-forming, antibody-dependent, cytotoxic cells with monocytic properties are present in rheumatoid synovial tissue. Scand J Rheumatol (1981) 0.75
Cerebral venous thrombosis and Escherichia coli infection in neonates. Acta Paediatr (2003) 0.75
Monocyte cytotoxicity in connective tissue diseases. Correlation with disease groups. Scand J Rheumatol (1981) 0.75
[Hemangioma and vascular malformations. Diagnosis and treatment]. Tidsskr Nor Laegeforen (1997) 0.75
Identification and functional characterization of monocytes in rheumatoid synovial fluid. Int Arch Allergy Appl Immunol (1981) 0.75
[Rotavirus in stools from hospitalized children]. Tidsskr Nor Laegeforen (1989) 0.75
[Utilization of anti-infective agents in pediatric departments in health region 2]. Tidsskr Nor Laegeforen (1999) 0.75
Tumour necrosis factor receptor superfamily member 6 gene mutation detection by denaturing high-performance liquid chromatography. Scand J Immunol (2004) 0.75
Infection with human cytomegalovirus (HCMV) stimulates monocyte production of complement factor 3. Arch Virol (1997) 0.75
[Principles and mechanism of action of drug therapy of rheumatoid arthritis]. Tidsskr Nor Laegeforen (1980) 0.75
Lymphocytes from synovial tissue of a boy with X-linked hypogammaglobulinemia and chronic polyarthritis. Arthritis Rheum (1979) 0.75
[Chest X-ray examination as a screening procedure. Experiences from the armed forces in 1978]. Tidsskr Nor Laegeforen (1982) 0.75
Antibody-dependent cytotoxicity mediated by cells eluted from synovial tissues of patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Scand J Immunol (1977) 0.75
[Recent methods in histologic diagnosis of tumors. II. Electron microscopy]. Tidsskr Nor Laegeforen (1983) 0.75
[Tuberculosis in Norwegian children--diagnostic challenges]. Tidsskr Nor Laegeforen (2000) 0.75
[Nutritional support of children with cancer]. Tidsskr Nor Laegeforen (1987) 0.75
Antibiotic susceptibility of blood culture isolates after nearly two decades with netilmicin and ampicillin in neonatal septicaemia. APMIS (1999) 0.75
[Diagnosis and treatment of infections in a neonatal unit--bacterial and fungal infections]. Tidsskr Nor Laegeforen (1993) 0.75
[Recent methods in the histologic diagnosis of tumors. I. Immunohistochemistry]. Tidsskr Nor Laegeforen (1983) 0.75
Characterization of antibody-dependent cell-mediated cytotoxicity in rheumatoid synovial fluid. Scand J Rheumatol (1981) 0.75